These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29662632)

  • 1. Regulation of breast cancer induced bone disease by cancer-specific IKKβ.
    Marino S; Bishop RT; Capulli M; Sophocleous A; Logan JG; Mollat P; Mognetti B; Ventura L; Sims AH; Rucci N; Ralston SH; Idris AI
    Oncotarget; 2018 Mar; 9(22):16134-16148. PubMed ID: 29662632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis.
    Peramuhendige P; Marino S; Bishop RT; de Ridder D; Khogeer A; Baldini I; Capulli M; Rucci N; Idris AI
    Sci Rep; 2018 Jan; 8(1):39. PubMed ID: 29311633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
    Marino S; Bishop RT; Mollat P; Idris AI
    Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
    Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
    Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.
    Bishop RT; Marino S; Carrasco G; Li B; Allen RJ; Sparatore A; Ottewell PD; Mollat P; Sims AH; Capulli M; Wang N; Idris AI
    Cancer Lett; 2020 Sep; 488():27-39. PubMed ID: 32474152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
    Bishop RT; Marino S; de Ridder D; Allen RJ; Lefley DV; Sims AH; Wang N; Ottewell PD; Idris AI
    Cancer Lett; 2019 May; 450():76-87. PubMed ID: 30790681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
    Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y
    Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression.
    Hu F; Wang C; Guo S; Sun W; Mi D; Gao Y; Zhang J; Zhu T; Yang S
    Biochim Biophys Acta; 2011 Mar; 1809(3):200-10. PubMed ID: 21241837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
    Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
    J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arenobufagin, isolated from toad venom, inhibited epithelial-to-mesenchymal transition and suppressed migration and invasion of lung cancer cells via targeting IKKβ/NFκB signal cascade.
    Zhao J; Zhang Q; Zou G; Gao G; Yue Q
    J Ethnopharmacol; 2020 Mar; 250():112492. PubMed ID: 31866511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone-related protein and bone metastases.
    Guise TA
    Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo.
    Marino S; Bishop RT; Carrasco G; Logan JG; Li B; Idris AI
    Calcif Tissue Int; 2019 Aug; 105(2):193-204. PubMed ID: 30929064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
    Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
    Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
    Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
    Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
    Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
    J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate.
    Pore SK; Hahm ER; Latoche JD; Anderson CJ; Shuai Y; Singh SV
    Carcinogenesis; 2018 Feb; 39(2):134-145. PubMed ID: 29040431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo.
    Guise TA; Yin JJ; Thomas RJ; Dallas M; Cui Y; Gillespie MT
    Bone; 2002 May; 30(5):670-6. PubMed ID: 11996903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.
    El-Shennawy L; Dubrovskyi O; Kastrati I; Danes JM; Zhang Y; Whiteley HE; Creighton CJ; Frasor J
    Cancer Res; 2018 Feb; 78(4):974-984. PubMed ID: 29229606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.